BUZZ-Shares of some obesity drug developers fall after Merck signs $2 bln deal to develop oral obesity drug

Reuters12-18 22:28
BUZZ-Shares of some obesity drug developers fall after Merck signs $2 bln deal to develop oral obesity drug

** Shares of obesity drug developers Structure Therapeutics GPCR.O and Viking Therapeutics VKTX.O fall between 7% and 8% in premarket trading

** GPCR down 7.2% at $29.20 and VKTX down 8.3% at $42.80

** Merck MRK.N signed a deal worth up to $2 bln with Hansoh Pharma 3692.HK to develop and sell the Chinese biotech's experimental oral obesity drug

** "We wonder whether this was the right deal for them, given the highly competitive nature of the space" - Brokerage BMO Capital Markets

** "This asset is preclinical and well behind Lilly's orforglipron, Structure's '1290, and Pfizer's danuglipron" - brokerage

** "Consequentially, we expect GPCR shares to be under pressure today" - BMO Capital Markets

** "From our conversations with clients, Merck represents one of the most likely acquirers of Viking; as a result, Viking shares will understandably sell off today" - Brokerage William Blair

** Companies such as GPCR and VKTX, as well as Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, are developing oral weight-loss treatments in the hopes of providing patients with a convenient dosing option

** Up to last close, GPCR down 22.8% while VKTX up 150.9% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment